Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

Homecas127984-74-1

127984-74-1

127984-74-1 structural image
Product Name: Lanreotide Acetate
Formula: C54H69N11O10S2
Synonyms: 3-(2-Naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-threoninamide cyclic (2→7)-disulfide acetate;Angiopeptin acetate;BIM-23014C
Inquiry

SAFETY INFORMATION

Signal word Warning
Pictogram(s)

Health Hazard
GHS08
GHS Hazard Statements H361:Reproductive toxicity
Precautionary Statement Codes P281:Use personal protective equipment as required.

COMPUTED DESCRIPTORS

Molecular Weight 1096.3 g/mol
XLogP3 2.5
Hydrogen Bond Donor Count 13
Hydrogen Bond Acceptor Count 14
Rotatable Bond Count 17
Exact Mass 1095.46702979 g/mol
Monoisotopic Mass 1095.46702979 g/mol
Topological Polar Surface Area 406 Ų
Heavy Atom Count 77
Formal Charge 0
Complexity 2000
Isotope Atom Count 0
Defined Atom Stereocenter Count 0
Undefined Atom Stereocenter Count 9
Defined Bond Stereocenter Count 0
Undefined Bond Stereocenter Count 0
Covalently-Bonded Unit Count 1
Compound Is Canonicalized Yes

PRODUCT INTRODUCTION

description

Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor. Lanreotide is manufactured by the company, Ipsen Pharmaceuticals as lanreotide acetate, and marketed as Somatuline. It is approved in several countries worldwide, including the United Kingdom, Australia, and Canada. Lanreotide was first approved for use in the United States by the FDA on August 30, 2007.

RELATED SUPPLIERS